These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37725166)

  • 1. Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab.
    VandeVrede L; La Joie R; Horiki S; Mundada NS; Koestler M; Hwang JH; Ljubenkov PA; Rojas JC; Rabinovici GD; Boxer AL; Seeley WW
    Acta Neuropathol; 2023 Nov; 146(5):777-781. PubMed ID: 37725166
    [No Abstract]   [Full Text] [Related]  

  • 2. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering.
    Cummings J; Aisen P; Lemere C; Atri A; Sabbagh M; Salloway S
    Alzheimers Res Ther; 2021 May; 13(1):98. PubMed ID: 33971962
    [No Abstract]   [Full Text] [Related]  

  • 3. "Aducanumab" making a comeback in Alzheimer's disease: An old wine in a new bottle.
    Behl T; Kaur I; Sehgal A; Singh S; Sharma N; Makeen HA; Albratty M; Alhazmi HA; Felemban SG; Alsubayiel AM; Bhatia S; Bungau S
    Biomed Pharmacother; 2022 Apr; 148():112746. PubMed ID: 35231697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.
    Salloway S; Chalkias S; Barkhof F; Burkett P; Barakos J; Purcell D; Suhy J; Forrestal F; Tian Y; Umans K; Wang G; Singhal P; Budd Haeberlein S; Smirnakis K
    JAMA Neurol; 2022 Jan; 79(1):13-21. PubMed ID: 34807243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.
    Budd Haeberlein S; Aisen PS; Barkhof F; Chalkias S; Chen T; Cohen S; Dent G; Hansson O; Harrison K; von Hehn C; Iwatsubo T; Mallinckrodt C; Mummery CJ; Muralidharan KK; Nestorov I; Nisenbaum L; Rajagovindan R; Skordos L; Tian Y; van Dyck CH; Vellas B; Wu S; Zhu Y; Sandrock A
    J Prev Alzheimers Dis; 2022; 9(2):197-210. PubMed ID: 35542991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aducanumab: The first targeted Alzheimer's therapy.
    Yang P; Sun F
    Drug Discov Ther; 2021; 15(3):166-168. PubMed ID: 34234067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aducanumab: First Approval.
    Dhillon S
    Drugs; 2021 Aug; 81(12):1437-1443. PubMed ID: 34324167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice.
    Kastanenka KV; Bussiere T; Shakerdge N; Qian F; Weinreb PH; Rhodes K; Bacskai BJ
    J Neurosci; 2016 Dec; 36(50):12549-12558. PubMed ID: 27810931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Why aducanumab is important.
    Cummings J
    Nat Med; 2021 Sep; 27(9):1498. PubMed ID: 34413516
    [No Abstract]   [Full Text] [Related]  

  • 10. Aducanumab: look before leaping.
    Perlmutter JS
    Nat Med; 2021 Sep; 27(9):1499. PubMed ID: 34413517
    [No Abstract]   [Full Text] [Related]  

  • 11. Aducanumab: Appropriate use recommendations.
    Cummings J; Salloway S
    Alzheimers Dement; 2022 Mar; 18(3):531-533. PubMed ID: 34314093
    [No Abstract]   [Full Text] [Related]  

  • 12. Amyloid Cascade into Clarity.
    Weitz TM; Town T
    Immunity; 2016 Oct; 45(4):717-718. PubMed ID: 27760336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Aducanumab and Alzheimer's disease: a critical reflection.].
    Vanacore N; Blasimme A; Canevelli M
    Recenti Prog Med; 2021; 112(7):495-498. PubMed ID: 34263875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biogen's aducanumab raises hope that Alzheimer's can be treated at its source.
    Patel KR
    Manag Care; 2015 Jun; 24(6):19. PubMed ID: 26182718
    [No Abstract]   [Full Text] [Related]  

  • 15. Alzheimer disease neuropathology in a patient previously treated with aducanumab.
    Plowey ED; Bussiere T; Rajagovindan R; Sebalusky J; Hamann S; von Hehn C; Castrillo-Viguera C; Sandrock A; Budd Haeberlein S; van Dyck CH; Huttner A
    Acta Neuropathol; 2022 Jul; 144(1):143-153. PubMed ID: 35581440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alzheimer's disease: the controversial approval of Aducanumab.
    Tagliavini F; Tiraboschi P; Federico A
    Neurol Sci; 2021 Aug; 42(8):3069-3070. PubMed ID: 34322762
    [No Abstract]   [Full Text] [Related]  

  • 17. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
    Sevigny J; Chiao P; Bussière T; Weinreb PH; Williams L; Maier M; Dunstan R; Salloway S; Chen T; Ling Y; O'Gorman J; Qian F; Arastu M; Li M; Chollate S; Brennan MS; Quintero-Monzon O; Scannevin RH; Arnold HM; Engber T; Rhodes K; Ferrero J; Hang Y; Mikulskis A; Grimm J; Hock C; Nitsch RM; Sandrock A
    Nature; 2016 Sep; 537(7618):50-6. PubMed ID: 27582220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aducanumab Therapy Ameliorates Calcium Overload in a Mouse Model of Alzheimer's Disease.
    Gamage KK; Kumar S
    J Neurosci; 2017 Apr; 37(17):4430-4432. PubMed ID: 28446659
    [No Abstract]   [Full Text] [Related]  

  • 19. Aducanumab for the treatment of Alzheimer's disease.
    Tagliapietra M
    Drugs Today (Barc); 2022 Oct; 58(10):465-477. PubMed ID: 36305541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The European Medicines Agency rejects the authorization of aducanumab for Alzheimer's disease].
    Dal-Ré R
    Rev Neurol; 2022 Mar; 74(6):207-208. PubMed ID: 35275397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.